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In this issue of Developmental Cell, Nacerddine et al.
(2005) describe a targeted germ line mutation of the
mouse SUMO-specific E2 Ubc9, which abrogates the
SUMO conjugation pathway, broadly crippling nuclear
function in proliferating cells of the early embryo. This
study reveals the wide-ranging roles for this protein
modifier in nuclear organization, chromosome segre-
gation, and Ran-driven nucleo-cytoplasmic transport.
The awarding of the 2004 Nobel Prize in Chemistry to
Ciechanover, Hershko, and Rose for their groundbreak-
ing work on ubiquitin provided proper recognition for
what cell biologists have long appreciated: the funda-
mental importance of this pathway in essentially all ba-
sic cellular processes (Hershko and Ciechanover, 1998).
In recent years it has become clear that ubiquitin is part
of a family of proteins that share both structure and
mechanism of conjugation to substrate proteins, but
which signal a diverse set of outcomes in the cell
(Welchman et al., 2005). Although our understanding
of the roles these pathways play in embryonic develop-
ment has lagged behind, the study from the Dejean lab
in this issue of Developmental Cell (Nacerddine et al.,
2005) may be a harbinger of progress to come.
Of the ubiquitin-like proteins, SUMO is the best stud-
ied, both in terms of potential function and specifics of
the enzymes involved in conjugation and deconjugation
(for a recent review, see Hay, 2005). Similar to ubiquiti-
nation, sumoylation involves multiple enzymatic activi-
ties acting sequentially to promote covalent attachment
to lysine residues in target proteins. For ubiquitin there
is a single E1 activating enzyme, over 30 different mam-
malian E2 conjugating enzymes, and hundreds of differ-
ent E3 ubiquitin ligases that mediate substrate specific-
ity (Lorick et al., 2005). A related but distinct set of
enzymatic activities carries out SUMO conjugation, but
there is one important difference. Sumoylation utilizes
only a single E2, Ubc9 (more formally known as UBE2I),
which directly interacts with substrates that are often
modified on a lysine lying within a specific consensus
sequence (see Hay, 2005). With specificity residing in
the SUMO E2 activity, the still rather limited number of
SUMO E3s identified to date may instead serve to en-
hance the sumoylation reaction.
Steady-state levels of SUMO conjugation are also
influenced by the activity of specific desumoylating en-
zymes, of which perhaps six exist in mammals, and the
right balance must be struck between conjugation and
deconjugation for SUMO-influenced processes to un-
fold properly. In fact, recent analysis of a mutation in the
mouse gene for the desumoylating enzyme Senp1 has
shown that SUMO homeostasis is critical for proper
development of the placenta (Yamaguchi et al., 2005).
Because Ubc9 represents such a critical nexus in the
sumoylation process, it is not surprising that loss ofUbc9 function leads to even more profound defects.
Although Ubc9 mutant embryos progress far enough
to undergo implantation, likely due to perdurance of ma-
ternal protein during preimplantation cleavage stages,
they fail to thrive after the onset of active proliferation
that defines the early postimplantation period. Using the
technique of blastocyst outgrowth culture to mimic this
early phase of postimplantation development, Nacerd-
dine et al. (2005) have been able to characterize a re-
markable range of defects in nuclear structure and func-
tion that illustrate roles for sumoylation in chromosome
condensation and segregation, nuclear morphology,
and subnuclear structure, as well as establishment and
maintenance of the RanGTPase gradient across the nu-
clear envelope, a critical element in nucleo-cytoplasmic
transport. Defects in any one of these processes alone
would no doubt gravely affect viability, but together
they lead to profound and catastrophic consequences
for the actively proliferating cells of the early embryo.
With so many proteins capable of being sumoylated,
there may be many key targets sharing responsibility for
the defects observed in Ubc9 mutant embryos. How-
ever, the usual suspects, RanGAP1 and PML, two of
the earliest identified SUMO substrates, probably have
a role to play in the collapse of the Ran gradient and ab-
normalities in one subnuclear domain, respectively. The
sumoylated form of RanGAP1 normally is found at the
cytoplasmic face of the nuclear pore complex (NPC),
and previous studies have suggested that this localiza-
tion is essential for RanGAP1’s role in Ran-dependent
nucleo-cytoplasmic transport (for review, see Melchior,
2000). It is still something of a mystery, though, why tar-
geting to the NPC, or sumoylation per se, is functionally
necessary, given that the yeast RanGAP1 homolog is
neither SUMO modified nor localized specifically at the
NPC. Null mutation of mouse RanGAP1 results in early
embryonic arrest (DeGregori et al., 1994). However, com-
pared to the Ubc9 knockout, viable RanGAP1 mutant
embryos could be recovered at slightly later postimplan-
tation stages. Thus, complete lack of RanGAP1 activity
appears less severe than total breakdown of the SUMO
system, suggesting that impaired RanGAP1 function is
just one of many defects conspiring to undermine viabil-
ity of Ubc9 mutants. Mutation of PML, conversely, has no
developmental phenotype (Wang et al., 1998), despite its
key role in the assembly of PML nuclear bodies, discrete
subnuclear domains implicated in various cancers and
other human disease. PML must be sumoylated in order
to recruit more than 50 other proteins to these structures
(for review, see Negorev and Maul, 2001). In the Ubc9
mutant, PML remains unsumoylated, and normal PML
nuclear bodies fail to form. Perhaps a mislocalized PML
protein, inappropriately consorting with different protein
partners, may be worse than no PML at all.
Further insight into the specific developmental pro-
cesses regulated by Ubc9-mediated sumoylation, in-
cluding events occurring at later embryonic stages,
must await implementation of conditional mutagenesis
strategies. However, the present study, by establishing
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728the essential nature of SUMO posttranslational modifi-
cation and revealing the breadth of fundamental cellular
processes affected by loss of Ubc9 function, provides
an important framework for future work.
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